On July 1, Samsung Bioepis Co., Ltd. announced that the FDA has approved PYZCHIVA (ustekinumab-ttwe), a biosimilar referencing STELARA (ustekinumab). PYZCHIVA is approved for the treatment of moderate ...
Hyderabad: CuraTeQ Biologics Private Limited, a wholly owned subsidiary of Aurobindo Pharma Limited, has received a Notice of ...
Aurobindo Pharma's subsidiary receives Health Canada NOC for Dyrupeg, confirming its pegylated filgrastim biosimilar's safety ...
The MarketWatch News Department was not involved in the creation of this content. -- JAMP Pharma Group launches PrPexegra(R), a biosimilar alternative to the reference product PrNeulasta(R) ...
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Kashiv Biosciences, LLC (“Kashiv” or the “Company”) is pleased to announce that the U.S. Food and Drug Administration (“FDA”) has approved its Biologics License ...
Aydin Harston Ph.D., Alexander Shaver Ph.D. FDA approves Omylco® (omalizumab), first biosimilar of Xolair®. After Q1, FDA and EMA on track for a record number of biosimilar authorizations in 2025.
Samsung Bioepis has released its Third Quarter 2024 Biosimilar Market Report, which includes the latest Average Sales Price information of all biosimilars and reference products available in the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback